DIAGNOSTIC TEST 620
Autoimmune Nodopathy/CIDP – Screen IgG
Diagnostic test for antibodies against NF155 (IgG), NF186 (IgG), CNTN1 (IgG), and CASPR1 (IgG). For suspicion of Inflammatory Neuropathy/Autoimmune Nodopathy.
Available as urgent test with results within 48 h.
Indication
Suspicion of Inflammatory Neuropathy/Autoimmune Nodopathy that is refractory to standard treatment.
Sample material
Serum
- Minim. volume: 0,5 mL
Transport
Within Sweden
- room temperature
International
- cold
Method
Cell-Based Assay (CBA), Indirect immunofluorescence (IIF)
Reference interval
- <1:10 negative
Result
Results are reported as negative or positive. A positive result is followed by a titer.
Interpretation
Autoimmune nodopathies have until recently been regarded as subgroups of CIDP but are distinct in both disease course and treatment. They are now regarded as separate disorders.
The panel includes the analysis of the following auto-antibodies that may be helpful in the investigation of patients with CIDP-like symptoms:
- Neurofascin-155 and Neurofascin-186 antibodies (IgG). Neurofascin-155 (NF155) is a paranodal protein, while Neurofascin-186 (NF186) is a protein present in the nodes of Ranvier. IgG antibodies against NF155 and NF186 have been reported in autoimmune nodopathy. The simultaneous presence of antibodies against NF155 and NF186 is seen in pan-neurofascin nodopathy.
- Contactin-1 antibodies (IgG). Contactin-1 (CNTN1) is a paranodal protein. IgG antibodies against CNTN1 have been reported in autoimmune nodopathy.
- CASPR1 antibodies (IgG). Contactin-associated protein 1 (CASPR1) is a paranodal protein. IgG antibodies against CASPR1 have been reported in autoimmune nodopathy.
References
- Van den Bergh PYK et al. J Peripher Nerv Syst. 2021. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. PMID: 34085743
- Dong M et al. Clin Neurol Neurosurg. 2022. Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy. PMID: 36401951
- Querol LA et al. Neurotherapeutics. 2022. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. PMID: 35378684
- Cortese A et al. Neurol Neuroimmunol Neuroinflamm. 2019. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. PMID: 31753915
- Delmont E et al. Brain. 2017. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. PMID: 28575198
- Appeltshauser L et al. Brain. 2023. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage. PMID: 36346134
Need pricing information?
How to order
This test is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.5 mL serum (plain serum tubes without additives).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18